Pharmaceutical Sciences
Global

Pharmaceutical Sciences Experts

Frank G. Haluska


Pharmaceutical Sciences
BioCancell Therapeutics 
Israel

Biography

Dr. Haluska has served as BioCanCell’s CEO since October 2016. He most recently served as Chief Medical Officer and Senior Vice President of Clinical R&D at ARIAD Pharmaceuticals, Inc., where he held overall responsibility for clinical development strategy. At ARIAD he led the clinical development and approval of ponatinib (marketed as Iclusig) in the US, EU and other territories, as well as the development of brigatinib (marketed as Alunbrig) approved in the US by the FDA. Dr. Haluska graduated from Harvard College and the University of Pennsylvania School of Medicine, undertook medical training at Massachusetts General Hospital (MGH) and the Dana-Farber Cancer Institute (DFCI), and a fellowship at the Massachusetts Institute of Technology Center for Cancer Research. He became assistant professor of medicine at Harvard Medical School, and leader of the melanoma research programs at the MGH Cancer Center and the DFCI through the Dana-Farber Harvard Cancer Center. Subsequently he was deputy director of the Tufts New England Medical Center Cancer Center. He currently serves on the Board of Directors at Vedantra Pharmaceuticals and as a flight surgeon in the U.S. Air Force and the Massachusetts Air National Guard with the rank of Colonel.

Research Interest

Pharmaceutical Sciences 

Global Experts from Israel

Global Experts in Subject

Share This Profile
Recommended Conferences
View more